RESEARCH PEPTIDE FUNDAMENTALS
Four Peptides Patients Actually Ask About — Read The Trial Data First
GHK-Cu, PT-141, retatrutide, and semaglutide are the research peptides most discussed in clinical settings. Here is what the published research says each one does, what it does not do, and where the evidence runs out.
GHK-Cu
A copper-binding tripeptide the body already makes — well studied as a topical cosmetic ingredient for collagen and hair, essentially unstudied as an injectable.
Read the research →
PT-141
Bremelanotide — a melanocortin receptor agonist approved for one specific condition in one specific patient group. Everything else discussed about it is off-label.
Read the research →
Retatrutide
A triple hormone-receptor agonist still in Phase 3 trials, with the largest Phase 2 weight-loss numbers reported for any incretin-class compound so far — and no approval anywhere yet.
Read the research →
Semaglutide
The lead compound on this desk — a GLP-1 receptor agonist with the deepest clinical trial record of the four, spanning diabetes, weight, heart, and kidney outcomes.
Read the research →The short version
Peptide Medicine NY does not sell anything, prescribe anything, or recommend a dose for anyone. It reads the published research behind four peptides that keep coming up — in clinics, in telehealth intake forms, and in online research communities — and states plainly what has actually been shown.
A peptide is a short chain of amino acids, the same building blocks that make up proteins, just smaller. The four peptides on this desk do four unrelated jobs. GHK-Cu is a copper-binding tripeptide studied for skin and tissue repair. PT-141 (bremelanotide) acts on brain receptors tied to sexual desire. Retatrutide and semaglutide are both incretin-class metabolic peptides studied for weight and blood sugar, at very different stages of development.
The blunt version, up front: semaglutide and PT-141 are FDA-approved prescription drugs for specific, narrow indications. GHK-Cu has real data as a topical cosmetic ingredient and almost none as an injectable. Retatrutide is not approved anywhere — it is still in trials. Read the individual pages for the detail.
The research peptides most discussed in clinical settings
These four sit together on this desk for one reason: they are, right now, the research peptides most discussed in clinical settings — the ones a nurse practitioner, a med-spa provider, or a reproductive-medicine clinician is most likely to field a question about after a patient reads something online. Beyond that, they do not have much in common. Four different mechanisms, four different regulatory realities, four different depths of evidence.
- GHK-Cu — a copper-binding tripeptide studied for collagen synthesis, wound repair, and hair-follicle biology. Long safety record topically; effectively no human data injected.
- PT-141 — bremelanotide, a melanocortin-receptor agonist FDA-approved for hypoactive sexual desire disorder in premenopausal women, and discussed off-label well beyond that population [8][9].
- Retatrutide — an investigational GIP/GLP-1/glucagon triple agonist that has posted the largest Phase 2 weight-loss numbers reported for any incretin-class compound to date, with no Phase 3 results published yet [14].
- Semaglutide — the lead compound here, a GLP-1 receptor agonist with the broadest and deepest clinical trial program of the four, spanning diabetes, weight, cardiovascular, and kidney outcomes [16][17][18][19][20][21][22].
Read each one on its own page, or jump straight to the side-by-side comparison.
What are research peptides?
"Research peptide" is a loose, often misleading label. It gets used for approved prescription drugs (semaglutide, bremelanotide), for legal cosmetic ingredients sold as serums (GHK-Cu), and for compounds with zero regulatory approval sold to researchers as "not for human consumption" (retatrutide, and GHK-Cu again in its injectable form). Same phrase, three completely different risk pictures.
What unites them structurally is size and origin: each is a short synthetic chain of amino acids, modeled on or related to a molecule the body already produces or responds to — GHK is a natural collagen-fragment sequence, bremelanotide is derived from the melanocortin system, and the two metabolic peptides mimic gut hormones released after eating. None of that makes a compound automatically safe, automatically effective, or automatically legal to use the way a given source markets it. The regulatory status of each is stated plainly on its own page, not buried in fine print.
How this desk reads the evidence
Every claim on this site traces back to a specific study, trial, or regulatory document, cited by number to a single shared reference list. Where the evidence is a large randomized trial, that is stated. Where it is a Phase 2 signal, a rodent study, or a case report, that is stated too — the strength of a claim matters as much as the claim itself.
Community-reported effects — what people actually say happens when they use these compounds — are included, because pretending research communities do not exist does not make them go away. But every one of those paragraphs is labeled anecdotal, not clinical evidence, and none of them comes with a dose. This desk does not tell anyone what to take, how much, or how often. That is a conversation for a licensed clinician, not a website.